Abstract：
UNASSIGNED: Retinoblastoma is the most common primary intraocular malignancy of childhood. The present study was undertaken to overcome the scarcity of data regarding the epidemiology, demographic and clinical profile, and nature of the first health-care professional consulted.
UNASSIGNED: A retrospective analysis of medical records was performed for all cases of retinoblastoma who presented to the department of ophthalmology and oncology between 2010 and 2017. A total of 54 cases were reviewed.
UNASSIGNED: Unilateral disease was seen in 85.2% while 14.8% presented with bilateral disease with a median age of 3 years and 2 years, respectively, at diagnosis. The male: female ratio was 2:1. The most common presenting symptom was leukocoria which was noticed in 42 patients (77.7%), followed by red eye (33.3%) and proptosis (20.3%). The most common stage of presentation was Stage I (44.4%), followed by Stage IV (20.4%), Stage III (9.3%), and Stage II (5.6%). The median time to diagnosis was 8.7 months (range, 0.5-98.7 months), and the median time to treatment was 37.4 days (range, 0-645 days). Majority of the patients were referred by local ophthalmologists (48%), followed by general practitioners (20%), nurses (19%), and quacks (13%). Enucleation was the most preferred treatment modality (48.1%), followed by chemotherapy (33.3%), radiotherapy (13%), photocoagulation (3.7%), and exenteration (1.9%). The overall remission rate was 79.6%, while 12.3% had relapse and 7.4% died.
UNASSIGNED: The study showed a dire need for timely detection and treatment of retinoblastoma which is possible with improved awareness and better accessibility to health-care facilities. It also revealed a decrease in histopathological risk factors with chemoreduction.
UNASSIGNED: A retrospective analysis of medical records was performed for all cases of retinoblastoma who presented to the department of ophthalmology and oncology between 2010 and 2017. A total of 54 cases were reviewed.
UNASSIGNED: Unilateral disease was seen in 85.2% while 14.8% presented with bilateral disease with a median age of 3 years and 2 years, respectively, at diagnosis. The male: female ratio was 2:1. The most common presenting symptom was leukocoria which was noticed in 42 patients (77.7%), followed by red eye (33.3%) and proptosis (20.3%). The most common stage of presentation was Stage I (44.4%), followed by Stage IV (20.4%), Stage III (9.3%), and Stage II (5.6%). The median time to diagnosis was 8.7 months (range, 0.5-98.7 months), and the median time to treatment was 37.4 days (range, 0-645 days). Majority of the patients were referred by local ophthalmologists (48%), followed by general practitioners (20%), nurses (19%), and quacks (13%). Enucleation was the most preferred treatment modality (48.1%), followed by chemotherapy (33.3%), radiotherapy (13%), photocoagulation (3.7%), and exenteration (1.9%). The overall remission rate was 79.6%, while 12.3% had relapse and 7.4% died.
UNASSIGNED: The study showed a dire need for timely detection and treatment of retinoblastoma which is possible with improved awareness and better accessibility to health-care facilities. It also revealed a decrease in histopathological risk factors with chemoreduction.
摘要：
未经证实：视网膜母细胞瘤是儿童时期最常见的原发性眼内恶性肿瘤。本研究是为了克服流行病学数据的匮乏，人口统计学和临床概况，以及咨询的第一位医疗保健专业人员的性质。
UNASSIGNED：对2010年至2017年期间在眼科和肿瘤科就诊的所有视网膜母细胞瘤病例进行了病历回顾性分析。共审查54例。
UNASSIGNED：单侧疾病占85.2％，而14.8％的患者表现为双侧疾病，中位年龄为3岁和2岁，分别,在诊断。男女比例为2:1。最常见的症状是白细胞增多症，42例(77.7%)。其次是红眼(33.3%)和眼球突出(20.3%)。最常见的陈述阶段是第一阶段(44.4%)，其次是第四阶段(20.4%)，第三阶段(9.3%),和第二阶段(5.6%)。中位诊断时间为8.7个月（范围，0.5-98.7个月)，中位治疗时间为37.4天（范围，0-645天）。大多数患者由当地眼科医生转诊（48%），其次是全科医生(20%)，护士（19%），和庸医(13%)。眼球摘除是最优选的治疗方式(48.1%),其次是化疗(33.3%)，放疗（13%），光凝（3.7%），和放逐(1.9%)。总缓解率为79.6%,12.3%复发，7.4%死亡。
UNASSIGNED：该研究表明，迫切需要及时检测和治疗视网膜母细胞瘤，这可以通过提高意识和更好地利用医疗保健设施来实现。它还显示了化学还原的组织病理学危险因素的减少。
UNASSIGNED：对2010年至2017年期间在眼科和肿瘤科就诊的所有视网膜母细胞瘤病例进行了病历回顾性分析。共审查54例。
UNASSIGNED：单侧疾病占85.2％，而14.8％的患者表现为双侧疾病，中位年龄为3岁和2岁，分别,在诊断。男女比例为2:1。最常见的症状是白细胞增多症，42例(77.7%)。其次是红眼(33.3%)和眼球突出(20.3%)。最常见的陈述阶段是第一阶段(44.4%)，其次是第四阶段(20.4%)，第三阶段(9.3%),和第二阶段(5.6%)。中位诊断时间为8.7个月（范围，0.5-98.7个月)，中位治疗时间为37.4天（范围，0-645天）。大多数患者由当地眼科医生转诊（48%），其次是全科医生(20%)，护士（19%），和庸医(13%)。眼球摘除是最优选的治疗方式(48.1%),其次是化疗(33.3%)，放疗（13%），光凝（3.7%），和放逐(1.9%)。总缓解率为79.6%,12.3%复发，7.4%死亡。
UNASSIGNED：该研究表明，迫切需要及时检测和治疗视网膜母细胞瘤，这可以通过提高意识和更好地利用医疗保健设施来实现。它还显示了化学还原的组织病理学危险因素的减少。
